Etanercept
Brand names: Enbrel, Enbrel Mini, Enbrel Sureclick
At a glance
- Medicare prescriptions, 2024
- 354,297
- Medicare drug cost
- $2.76B
- Average cost per prescription
- $7,798
- Clinicians who prescribed it
- 6,772
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with: Rheumatoid Arthritis (RA) Psoriatic Arthritis (PsA) Ankylosing Spondylitis (AS) Plaque Psoriasis (PsO) Pediatric patients with: Polyarticular Juvenile Idiopathic Arthritis (pJIA), 2 years of age or older Juvenile Psoriatic Arthritis, 2 years of age or older (JPsA) Plaque Psoriasis, 4 years of age or older
From the FDA-approved prescribing information (label dated May 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: SERIOUS INFECTIONS and MALIGNANCIES WARNING: SERIOUS INFECTIONS and MALIGNANCIES See full prescribing information for complete boxed warning. SERIOUS INFECTIONS Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Enbrel should be discontinued if a patient develops a serious infection or sepsis during treatment. Perform test for latent TB; if positive, start treatment for TB prior to starting Enbrel. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. MALIGNANCIES Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers, including Enbrel. SERIOUS INFECTIONS Patients treated with Enbrel are at…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Rheumatology 75.6%
- Nurse Practitioners 9.0%
- Physician Assistants 6.3%
- Internal Medicine 4.8%
- Dermatology 1.6%
- Family Medicine 1.5%
- Pharmacists 0.3%
- Allergy & Immunology 0.2%
- General Practice 0.1%
- Hospitalist 0.1%
- Geriatric Medicine 0.1%
- Pediatrics 0.1%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 22% from 2019 to 2024.
Biggest change by state since 2019
- Puerto Rico +47%
- Virginia +35%
- Washington +35%
- Kentucky +34%
- Indiana +32%
- Alabama (smallest change) −1%
- Arizona (smallest change) +11%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
Drug makers reported $187,864 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Amgen Inc. $187,864
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.